Is Complement Alternative Pathway Disregulation Involved in Veno-Occlusive Disease of the Liver?  by Bucalossi, Alessandro et al.
Biol Blood Marrow Transplant 16:1747-1751, 2010 1749Letters to the EditorReply
In a careful examination of our recent review of
salvage therapies for steroid-refractory acute graft-
versus-host disease (aGVHD) [1], Greinix et al. have
rightfully identified that the discussion of extracorpo-
real photopheresis (ECP) did not include all published
data. Specifically, our review cited the results of a pilot
study conducted by Greinix et al. [2], but did not in-
clude a later report that summarized both the results
of the pilot study and a prospective phase II trial [3].
In their response to our review, Greinix et al. note
that therewere important differences in patient charac-
teristics and therapy between the pilot trial and the
phase II trial that might have contributed to more
encouraging responses. Compared with the pilot trial,
the phase II trial showed higher rates of complete
remission (CR) of aGVHD in patients with gastroin-
testinal involvement (73% vs 25%) and grade IV
disease (60%vs 12%).This does not appear to be a con-
sistent trend, however; the pilot trial showed higher
rates of CR of aGVHD in patients with grade II disease
(100% vs 85%), grade III disease (67% vs 43%), and
liver involvement (67% vs 55%). Moreover, the ability
to draw conclusions about the comparative efficacy of
ECP in grade IV aGVHD across the pilot and phase
II trials is limited by the small number of subjects
(n 5 5 in each trial).
Although limited to small, single-center studies, the
overall experience reported by Greinix et al. and other
published literature suggests that ECP can induce CR
of steroid-refractory aGVHD and can facilitate libera-
tion from glucocorticoids. We agree that prospective,
well-designed studies on refractory aGVHD are needed
to discern the true benefit of salvage therapies.REFERENCES
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Disease of the Liver?
Wewerepleased to read the article byCutler et al. [1]
recently published in BBMT. Veno-occlusive disease of
the liver (VOD) is a serious complication of hematopoi-
etic stem cell transplantation (HSCT), particularly
after busulfan (BU)-based conditioning regimens,
and it could be very important to identify biomarkers
useful to predict its occurrence. We agree with the au-
thors that the pathogenesis of VOD is multifactorial.
In this regard we have noticed that some clinical as-
pects can be commonly observed both in VOD and
HELLP (hemolysis, elevated liver enzymes, and low
platelet number) syndrome. VOD is thought to be ini-
tiated by injury to the area surrounding the central
vein; damage is seen in sinusoidal endothelial cells
(EC) and in hepatocytes in zone 3 of the liver acinus.
Structural damage continues with progressive venular
occlusion, culminating in widespread zonal liver dis-
ruption. Recently, several cases of HELLP syndrome
have been associated with complement disregulation
[2], which is frequently observed in aHUS (atypical
hemolytic uremic syndrome). In aHUS, microvascular
EC injury has been linked to excessive complement
activation via the alternative pathway (AP), in that ap-
proximately 50% of these patients have AP complement
activating missense mutations or functional variants in
genes encoding complement regulatory proteins: factor
H (CFH), factor I (CFI), membrane cofactor protein
(MCP), CFH-related proteins, C4b binding protein,
thrombomodulin, C3, and factor B [3-5].
A pilot study was conducted to identify sequence
variants of CFH and CFI in 7 patients who had under-
gone an allogeneic HSCTwith BU and cyclophospha-
mide (CY) conditioning regimen for acute myeloid
leukemia (AML). Three patients showed classical signs
of VOD according to the Seattle criteria within 35 days
from the transplant. The remaining 4 control patients
did not exhibit clinical signs of VOD. All samples, for
gene sequence evaluation, were obtained before
treatment for AML.
No CFI gene sequence variants were detected in
either VOD or control groups. Two variants of the
CFH gene were detected exclusively in the VOD
group. One was a novel intronic variant, IVS 18-86
T.C, whereas the other, p.E936D, had been previ-
ously associated with aHUS [5].
Our preliminary study might suggest that disregu-
lation of the complement system may represent the
first step of the process. These data could support
the conclusions of Cutler et al. [1], suggesting the
1750 Biol Blood Marrow Transplant 16:1747-1751, 2010Letters to the Editordevelopment of endothelial damage only in a subset of
patients. However, because VOD is a rather rare dis-
ease, to confirm our results it is necessary to enrol
many more patients in a multicenter study.REFERENCES
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Age and Total-Body
Irradiation in Addition to
Corticosteroid Dose Are
Important Risk Factors for
Avascular Necrosis of the Bone
This report by McAvoy et al. [1] highlights impor-
tant aspects of the risk factors for the development of
avascular necrosis (AVN) of the bone after hematopoi-
etic cell transplantation (HCT). They show a clear
relationship between steroid exposure and impact of
steroid dose on the risk of developing AVN.Our group
has recently presented data of a retrospective case-
control study [2] and found some important differencescompared toMcAvoy’s findings.We analyzed a variety
of known risk factors in a cohort of patients (cases, 50;
controls, 156) without a pretransplant diagnosis of
AVN undergoing allogeneic HCT (allo-HCT) from
a human leukocyte antigen (HLA)-identical related
donor (n 5 133) or HLA-matched unrelated donor
(n 5 65) or umbilical cord HCT (n 5 6) after either
ablative (n5 142) or reduced-intensity (n5 64) prepar-
ative regimens. Median time from transplant to AVN
diagnosis was 1.2 years (range: 0.12-5.2). Median
follow-up was 3.7 years (range: 0.2-8.6) for AVN
patients versus 1.9 years (range: 0.3-9.0) for controls
(P\ .001). Patients with AVNwere significantly youn-
ger than controls at time of transplant (median age 37
versus 48 years, P \ .001) and were more likely to
have a history of tobacco use (68% versus 43%, P 5
.012). In univariate analyses, unrelated donor (48% of
AVN patients versus 30% of controls, P 5 .043), use
of total-body irradiation (TBI) (irrespective of dose)
in preparative regimens (72% versus 46%, P 5 .001),
and systemic steroids (SS) to treat graft-versus-host
disease (GVHD) (98% versus 84%, P5 .009) were as-
sociatedwith increased risk of AVN.Mean peak dose of
SS was higher in the AVN patients versus controls (1.6
versus 1.4mg/kg/day prednisone equivalent,P5 .014).
The median duration of SS treatment prior to AVN
diagnosis was 228 days (range: 104-400), and 60% of
these patients were receiving SS at the time of AVN
diagnosis. Median total duration of SS therapy in
patients with AVN was 712 days (range: 293-1195)
and was significantly longer compared with the control
cohort (383 days; range: 38-630) (P\ .001). Interest-
ingly, this association was seen only in patients age
.40 years (AVN versus control; 852 days [range:
591-1616] versus 416 days [range: 15-596], P\ .001].
The finding of steroid exposure and dose relationship
(function of dose and duration) was similar to what
was seen in the McAvoy study, although duration of
steroid use was not specifically addressed. There were
no significant differences in ethnicity, gender, diagno-
sis, disease status, bodymass index (BMI), bone density,
incidence or severity of GVHD, or survival between
the AVN and control patients. Inmultivariate analyses,
age (\40 years; odds ratio [OR]5 2.55, P5 .008), TBI
(OR5 2.29, P5 .027), and SS (.1 mg/kg/day; OR5
3.48, P5 0.052) were independent predictors of AVN.
Our study identifies the use of TBI in preparative
regimens as a risk factor for development of AVN.
This factor was not identified in the McAvoy study,
but has been previously reported [3]. In our study,
age \40 years was associated with a higher risk of
AVN, and is an important observation and differs
from previous study, where older age has been associ-
ated with AVN [4]. The McAvoy study was controlled
for age between cases and controls and thus could not
address this. Pretransplant smoking was identified as
a significant factor in univariate analyses and has
